Anika Therapeutics (ANIK) Cost of Revenue (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Cost of Revenue data on file, last reported at $10.6 million in Q1 2026.

• On a quarterly basis, Cost of Revenue fell 7.59% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $48.1 million, a 6.15% increase from a year earlier, with the FY2025 full-year figure at $49.0 million, up 11.62% from the prior year.
• Cost of Revenue for Q1 2026 stood at $10.6 million, down from $11.4 million in the prior quarter.
• Over the last five years, Cost of Revenue for ANIK reached as high as $17.5 million in Q3 2022 and fell as low as -$8.7 million in Q4 2023.
• Historically, Cost of Revenue has averaged $10.7 million across 5 years, with a median of $12.2 million in 2025.
• Across the five-year window, Cost of Revenue sank 137.1% in 2022 and soared 255.4% in 2024, its largest moves.
• Year by year, Cost of Revenue stood at -$6.6 million in 2022, then plunged by 32.15% to -$8.7 million in 2023, then surged by 255.4% to $13.5 million in 2024, then decreased by 15.14% to $11.4 million in 2025, then dropped by 7.18% to $10.6 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $10.6 million in Q1 2026, $11.4 million in Q4 2025, and $12.2 million in Q3 2025.